Precision Oncology, Precision Immunooncology, Phase I, Biomarker discovery
학력
2005.02 성균관대학교 대학원 내과학 박사
2002.06 성균관대학교 대학원 의학과 석사
1999.02 이화여자대학교 의과대학 졸업
약력/경력
2020.04 ~현재 삼성서울병원 혈액종양내과 교수
2019.04 ~ 현재 삼성서울병원 정밀의학연구소 혁신치료 센터장
2014.03 ~ 2020.03 삼성서울병원 혈액종양내과 부교수
2010.03 ~ 2014.02 삼성서울병원 혈액종양내과 조교수
2006.03 ~ 2010.02 삼성서울병원 혈액종양내과 임상조교수
학술지 논문
(2024)
Association of<i> ATM</i> and<i> ARID1A</i> in gastric carcinoma.
PATHOLOGY RESEARCH AND PRACTICE.
263,
(2024)
Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-09).
CANCER.
131,
1
(2024)
TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice.
FRONTIERS IN ONCOLOGY.
14,
(2024)
Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis.
PATHOLOGY RESEARCH AND PRACTICE.
261,
(2024)
The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer.
CANCERS.
16,
17
(2024)
Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY.
16,
8
(2024)
The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial.
CANCER LETTERS.
597,
(2024)
Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer.
CANCER PREVENTION RESEARCH.
17,
8
(2024)
CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells.
TRANSLATIONAL CANCER RESEARCH.
13,
7
(2024)
Clinical outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision in locally advanced rectal cancer with mesorectal fascia involvement.
Radiation Oncology Journal.
42,
2
(2024)
Favorable clinical efficacy of cytotoxic chemotherapy in patients with progressive desmoid tumors: a retrospective real-world study.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY.
29,
6
(2024)
Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer.
CANCER DISCOVERY.
14,
5
(2024)
Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
EUROPEAN JOURNAL OF CANCER.
203,
(2024)
Clinical Activity of TGF-b Inhibitor Vactosertib in Combination with Imatinib in Desmoid Tumors: A Multicenter Phase Ib/II Study.
CLINICAL CANCER RESEARCH.
30,
8
(2024)
Patient-derived tumor spheroid-induced angiogenesis preclinical platform for exploring therapeutic vulnerabilities in cancer.
BIOMATERIALS.
306,
(2024)
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
Journal for ImmunoTherapy of Cancer.
12,
3
(2024)
Comparative analysis of ARID1A mutations with mRNA levels and protein expression in gastric carcinoma.
Pathology Research and Practice.
255,
(2023)
Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer.
BIOMEDICINES.
11,
12
(2023)
Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data.
BIOMEDICINES.
11,
12
(2023)
Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer.
SCIENCE ADVANCES.
9,
47
특허/프로그램
인공신경망을 이용한 위암의 예후 예측 방법, 장치 및 프로그램.
10-2019-7003924.
20201207.
대한민국
위암의 예후 예측용 PD-L1 마커 및 이의 용도.
10-2017-0182665.
20201202.
대한민국
항암 보조치료법의 선택을 위한 혈액 마커 및 이를 이용한 치료법 선택의 방법.
10-2018-0041926.
20200709.
대한민국
위암의 항암제 치료 반응성 예측용 바이오마커 및 이의 용도.
10-2018-0005488.
20200331.
대한민국
위암의 항암제 내성 진단용 바이오마커 및 이의 용도.
10-2017-0143200.
20200131.
대한민국
MCT의 발현 억제제 또는 활성 억제제를 유효성분으로 포함하는 암의 치료 또는 전이 억제용 조성물.
10-2018-0161963.
20200130.
대한민국
암의 복막 전이 진단을 위한 MCT4의 용도 (Uses of MCT4 for Diagnosing Peritoneal Metastasis).
10-2016-0085613.
20191122.
대한민국
소화기암 환자의 면역치료 반응성 예측용 TIRAP 마커 및 이의 용도.
10-2017-0126732.
20190826.
대한민국
소화기암 환자의 면역치료 반응성 예측용 TLR3 마커 및 이의 용도.
10-2017-0126749.
20190826.
대한민국
소화기암 환자의 면역치료 반응성 예측용 TLR7 마커 및 이의 용도.
10-2017-0126743.
20190826.
대한민국
소화기암 환자의 면역치료 반응성 예측용 CISH 마커 및 이의 용도.
10-2017-0126728.
20190823.
대한민국
위암의 예후 예측용 마커 및 이의 용도.
10-2017-0126718.
20190823.
대한민국
MET 저해제에 대한 감수성 예측용 조성물.
10-2016-0103773.
20190530.
대한민국
항암제 저항성 또는 민감성 예측용 조성물.
10-2016-0120762.
20190503.
대한민국
위암 아형의 분류 방법(Methods for classifying subunits of gastric cancer).
10-2016-0048347.
20181204.
대한민국
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 (MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS).
11849123.2.
20180808.
폴란드
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 (MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS).
11849123.2.
20180808.
스페인
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 (MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS).
11849123.2.
20180808.
독일
위암 진단방법 및 이를 이용한 위암 진단 키트.
10-2015-0082538.
20170926.
대한민국
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
{Marker for Predicting Gastric Cancer Prognosis and Method for Predicting Gastric Cancer Prognosis Using the Same}.
13/994,072.
20160419.
미국
수상/공훈
2020 SKKU Excellence in Research Award
2019 (성균관대학교 의과대학 최우수 연구업적상)
2019 보건복지부 우수연구성과 공로상
2018 삼성서울병원 특별 의료 지표 공로상
2016 삼성서울병원 개원공로상
2016 삼성서울병원 최우수 연구업적상
2015 성균관대학교 최우수 연구업적상
학술회의논문
(2017)
NGS-guided Clinical Trials in Gastric Cancer.
2017 KCSG Annual Meeting.
대한민국
(2016)
Overview for Precision Medicine.
대한종양외과학회.
대한민국
(2016)
Clinical application of NGS in cancer.
기초의학학술대회.
대한민국
(2016)
Molecular targeted therapy for HCC: Learning from genome-matched trials in other solid cancer.
대한간암학회.
대한민국
(2016)
FPA144, a humanized monoclonal antibody for both FGFR2-amplified and nonamplified, FGFR2b-overexpressing gastric cancer patients..
American Society of Clinical Oncology.
미국
(2016)
Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy..
American Society of Clinical Oncology.
미국
(2016)
The NEXT-1 Trial at SMC: Is clinical sequencing beneficial to metastatic cancer patients?.
생화학분자생물학회지.
대한민국
(2016)
Clinical sequencing program in metastatic gastric cancer patients at SMC: translation from sequence - preclinical - clinical trials.
AACR.
미국
(2010)
A Phase II Trial of Neoadjuvant Erlotinib (TARCEVA) Followed by Surgery for Selected Patients with Stage IIIA, N2-Positive Non-Small Cell Lung Cancer.
Journal of Thoracic Oncology.
대한민국
(2010)
Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment.
Journal of Thoracic Oncology.
대한민국
(2010)
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor.
Journal of Thoracic Oncology.
대한민국
(2010)
Clinical impact of amphiregulin expression in EGFR wild-type non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Journal of Clinical Oncology.
미국
(2010)
Correlation of genetic polymorphisms in folate metabolic pathway genes with clinical outcomes in pemetrexed-treated advanced NSCLC patients..
Journal of Clinical Oncology.
미국
(2010)
Molecular profiling of pulmonary plemorphic carcinoma: Implications for targeted treatment of a rare lung malignancy..
Journal of Clinical Oncology.
미국
(2010)
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
Journal of Clinical Oncology.
미국
(2010)
Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment.
Journal of Clinical Oncology.
미국
(2010)
Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhbitor..
Journal of Clinical Oncology.
미국
(2010)
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy..
Journal of Clinical Oncology.
미국
발전기금
